SCHEMBL1719970

SCHEMBL1719970

Cn1c(-c2cccc(C(F)(F)F)c2)nc(I)c1C(=O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
XDH P47989 2/20 0.50
PIN1 Q13526 1/20 0.50
PTGS2 P35354 1/20 0.46
KMO O15229 2/20 0.46
KMT2A Q03164 5/20 0.46
EGLN1 Q9GZT9 1/20 0.43
MEN1 O00255 4/20 0.43
KDM4E B2RXH2 3/20 0.43
CYP1A2 P05177 2/20 0.43
CYP2C9 P11712 2/20 0.43
CYP2C19 P33261 2/20 0.43
HTT P42858 2/20 0.43
CYP2D6 P10635 1/20 0.43
NPC1 O15118 2/20 0.42
ATM Q13315 1/20 0.42
CFTR P13569 1/20 0.42
RAB9A P51151 1/20 0.41
NOTUM Q6P988 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1719263 0.87 RXRA (0.43) ALDH1A1SMN1; SMN2XDHPIN1KMO
SCHEMBL1719147 0.85 SMN1; SMN2 (0.50) ALDH1A1SMN1; SMN2XDHPIN1PTGS2
SCHEMBL1719478 0.84 XDH (0.50) ALDH1A1SMN1; SMN2XDHPIN1KMO
SCHEMBL1719231 0.84 ALDH1A1 (0.40) ALDH1A1PIN1KDM4ENPC1
SCHEMBL1720088 0.82 DHODH (0.44) XDH
SCHEMBL1720026 0.81 PTGS2 (0.49) ALDH1A1SMN1; SMN2XDHPIN1PTGS2
SCHEMBL1720102 0.81 ALDH1A1 (0.44) ALDH1A1SMN1; SMN2XDHPIN1KMO
SCHEMBL12672992 0.79 PTGS2 (0.47) ALDH1A1SMN1; SMN2XDHPIN1PTGS2
SCHEMBL1719194 0.78 GRIN1 (0.46) ALDH1A1SMN1; SMN2XDHPIN1KMO
SCHEMBL1719382 0.78 IRAK4 (0.45) LMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101687844-B Imidazole derivatives as CCR2 receptor antagonists HOFFMANN LA ROCHE 2013-11-13 CN disclosed
EP-2173735-B1 IMIDAZOLE DERIVATIVES AS CCR2 RECEPTOR ANTAGONISTS HOFFMANN LA ROCHE (CH) 2012-01-11 EP disclosed
US-7935707-B2 Imidazole derivatives HOFFMAN-LA ROCHE INC. (US) 2011-05-03 US disclosed
CN-101687844-A Imidazole derivatives as CCR2 receptor antagonists HOFFMANN LA ROCHE 2010-03-31 CN disclosed
US-20090012063-A1 Novel imidazole derivatives HOFFMANN-LA ROCHE, INC. 2009-01-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012063-A1 Novel imidazole derivatives CCR2, CCR1, CCR3 ALDH1A1 1556/4885SMN1; SMN2 3584/4885XDH 1490/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.